NEW YORK, March 30 (Reuters) - Prostate cancer vaccine Provenge has long incited passions unlike any other cancer therapy. Doctors who raised doubts about it received death threats. Health regulators ...

WASHINGTON - Medicare officials confirmed Thursday that the program will cover the $93,000 price tag for prostate-cancer drug Provenge, an innovative therapy that typically gives men suffering from an ...

Dendreon filed for bankruptcy protection on Monday after sales of Provenge fell way short of expectations and the company could not pay off a huge debt coming due. By Andrew Pollack Costly treatments ...

Medicare will pay $93,000 for the drug Provenge, a therapy that typically gives men suffering from prostate cancer an extra four months to live ["Medicare to pay for Provenge," News, March 31]. And ...

The company has leased a 158,000-sq.-ft. warehouse on Hanover Avenue.Seattle-based Dendreon (Nasdaq: DNDN) has announced that will set up its production line to manufacture Provenge, a drug to treat ...